[Federal Register Volume 85, Number 230 (Monday, November 30, 2020)]
[Notices]
[Pages 76576-76577]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-26257]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Solicitation of Nominations for Appointment to the Clinical 
Laboratory Improvement Advisory Committee (CLIAC)

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Centers for Disease Control and Prevention (CDC) is 
seeking nominations for membership on the CLIAC. The CLIAC consists of 
20 experts including the Chair who represents a diverse membership 
across laboratory specialties, professional roles (laboratory 
management, technical specialists, physicians, nurses) and practice 
settings (academic, clinical, public health), and includes a consumer 
representative.

DATES: Nominations for membership on the CLIAC must be received no 
later than March 1, 2021. Packages received after this time will not be 
considered for the current membership cycle.

ADDRESSES: All nominations should be mailed to Nancy Anderson, MMSc, 
MT(ASCP), CLIAC Secretary, Senior Advisor for Clinical Laboratories, 
Division of Laboratory Systems, Center for Surveillance, Epidemiology 
and Laboratory Services, Office of Public Health Scientific Services, 
Centers for Disease Control and Prevention, 1600 Clifton Road NE, 
Mailstop V24-3, Atlanta, Georgia 30329-4018; telephone (404) 498-2741; 
or via email at <a href="/cdn-cgi/l/email-protection#99dad5d0d8dad9fafdfab7fef6ef"><span class="__cf_email__" data-cfemail="d99a9590989a99babdbaf7beb6af">[email protected]</span></a>.

FOR FURTHER INFORMATION CONTACT: Heather Stang, MS, Deputy Branch 
Chief, Quality and Safety Systems Branch, Division of Laboratory 
Systems, Center for Surveillance, Epidemiology and Laboratory Services, 
Office of Public Health Scientific Services, Centers for Disease 
Control and Prevention, 1600 Clifton Road, NE, Mailstop V24-3, Atlanta, 
Georgia 30329-4018; telephone (404) 498-2769; <a href="/cdn-cgi/l/email-protection#c9819abda8a7ae89aaadaae7aea6bf"><span class="__cf_email__" data-cfemail="b6fee5c2d7d8d1f6d5d2d598d1d9c0">[email protected]</span></a>.

SUPPLEMENTARY INFORMATION: The Committee also includes three ex officio 
members (or designees), including the Director, CDC; the Administrator, 
Centers for Medicare and Medicaid Services (CMS); and the Commissioner, 
Food and Drug Administration (FDA). A nonvoting representative from the 
Advanced Medical Technology Association (AdvaMed) serves as the 
industry liaison. The Designated Federal Official (DFO) or their 
designee and the Executive Secretary are present at all meetings to 
ensure meetings are within applicable statutory, regulatory, and HHS 
General Administration manual directives.
    Nominations are being sought for individuals who have the expertise 
and qualifications necessary to contribute to the accomplishments of 
the committee's objectives. Nominees will be selected based on 
expertise in the fields of microbiology (including bacteriology, 
mycobacteriology, mycology, parasitology, and virology), immunology 
(including histocompatibility), chemistry, hematology, pathology 
(including histopathology and cytology), or genetic testing (including 
cytogenetics); from representatives in the fields of medical 
technology, bioinformatics, public health, and clinical practice; and 
from consumer representatives. Federal employees will not be considered 
for membership. Members may be invited to serve for up to four-year 
terms.
    Selection of members is based on candidates' qualifications to 
contribute to the accomplishment of CLIAC objectives (https://www.cdc.gov/cliac/).
    The U.S. Department of Health and Human Services policy stipulates 
that committee membership be balanced in terms of points of view 
represented, and the committee's function. Appointments shall be made 
without discrimination on the basis of age, race, ethnicity, gender, 
sexual orientation, gender identity, HIV status, disability, and 
cultural, religious, or socioeconomic status. Nominees must be U.S. 
citizens, and cannot be full-time employees of the U.S. Government. 
Current participation on federal workgroups or prior experience serving 
on a federal advisory committee does not disqualify a candidate; 
however, HHS policy is to avoid excessive individual service on 
advisory committees and multiple committee memberships. Committee 
members are Special Government Employees (SGEs), requiring the filing 
of financial disclosure reports at the beginning and annually during 
their terms. CDC reviews potential candidates for CLIAC membership each 
year and provides a slate of nominees for consideration to the 
Secretary of HHS for final selection. HHS notifies selected candidates 
of their appointment near the start of the term in July, or as soon as 
the HHS selection process is completed. Note that the need for 
different expertise varies from year to year and a candidate who is not 
selected in one year may be reconsidered in a subsequent year. 
Candidates should submit the following items:
    [squf] Current curriculum vitae, including complete contact 
information (telephone numbers, mailing address, email address)
    [squf] At least one letter of recommendation from person(s) not 
employed by the U.S. Department of Health and Human Services. 
(Candidates may submit letter(s) from current HHS employees if they 
wish, but at least one letter must be submitted by a person not 
employed by an HHS agency (e.g., CDC, NIH, FDA, etc.).
    Nominations may be submitted by the candidate, or by the person/
organization recommending the candidate.
    The Director, Strategic Business Initiatives Unit, Office of the 
Chief Operating Officer, Centers for Disease Control and Prevention, 
has been

[[Page 76577]]

delegated the authority to sign Federal Register notices pertaining to 
announcements of meetings and other committee management activities, 
for both the Centers for Disease Control and Prevention and the Agency 
for Toxic Substances and Disease Registry.

Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief 
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2020-26257 Filed 11-27-20; 8:45 am]
BILLING CODE 4163-18-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>